<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386606</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-204</org_study_id>
    <nct_id>NCT01386606</nct_id>
  </id_info>
  <brief_title>The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)</brief_title>
  <official_title>A Randomized, Single Blind, Multi-Center Phase II Study to Evaluate the Effect of Three Different Doses of Androxal and AndroGel on 24-Hour Luteinizing Hormone and Testosterone in Normal Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the effects of three doses of Androxal(enclomiphene citrate)on
      morning testosterone versus AndroGel(approved topical treatment)in men with low testosterone
      (&lt;350 ng/dL)after 6 weeks of continuous dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study will require 7 visits, which includes 2 overnight stays in a clinic. One visit is an
      eye exam. Blood samples are required at all visits including sampling every hour for a 24
      hour time period during the 2 overnight stays. A six month extension study will be available
      for all subjects completing the 6-week study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 Hour Average and Maximum Testosterone Concentration</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The primary efficacy endpoint will be 24-hour average (TTavg) and maximum (TTmax) testosterone concentration compared to baseline after 6 weeks of treatment.
Time points (in hours after dosing) at which testosterone concentration was measured are: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Leuteinizing Hormone (LH)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6</time_frame>
    <description>Changes in morning LH after continuous dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Follicle Stimulating Hormone (FSH)</measure>
    <time_frame>Baseline, Week 2, Week 4, Week 6</time_frame>
    <description>Changes in morning FSH after continuous dosing</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Enclomiphene Pharmacokinetic Parameters at Week 6 - Cmax.</measure>
    <time_frame>Week 6</time_frame>
    <description>The Cmax for plasma concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Enclomiphene Pharmacokinetic Parameters at Week 6 - Tmax.</measure>
    <time_frame>Week 6</time_frame>
    <description>The Tmax for plasma concentration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Enclomiphene Pharmacokinetic Parameters at Week 6 - AUC0-24.</measure>
    <time_frame>Week 6</time_frame>
    <description>The area under the curve for plasma concentration over time from zero to 24 hours (AUC0-24).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Secondary Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Androxal 6.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Androxal 6.25 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Androxal 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Androxal 12.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Androxal 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Androxal 25 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AndroGel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AndroGel 5G topical testosterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal (enclomiphene citrate)</intervention_name>
    <description>capsule oral
1X a day 6 weeks</description>
    <arm_group_label>Androxal 6.25 mg</arm_group_label>
    <arm_group_label>Androxal 12.5 mg</arm_group_label>
    <arm_group_label>Androxal 25 mg</arm_group_label>
    <other_name>Androxal</other_name>
    <other_name>low testosterone therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>topical gel
1X a day 6 weeks</description>
    <arm_group_label>AndroGel</arm_group_label>
    <other_name>topical testosterone</other_name>
    <other_name>testosterone gel</other_name>
    <other_name>exogenous testosterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males between the ages of 18 and 65 years of age exhibiting morning
             testosterone ≤350 ng/dL.

          -  All clinical laboratory tests within normal ranges (any clinically significant
             deviation of laboratory results will require approval of sponsor)

          -  Ability to complete the study in compliance with the protocol

          -  Ability to understand and provide written informed consent

          -  Agreement to use a condom, and with a fertile female partner, another form of
             contraception.

          -  Agreement to provide a semen sample in the clinic

        Exclusion Criteria:

          -  Use of an injectable, oral, topical, or subcutaneous pelleted testosterone within 3
             months prior to study

          -  Use of spironolactone, cimetidine, 5α-reductase inhibitors, hCG, androgen, estrogen,
             anabolic steroid, DHEA, or herbal hormone products during the study

          -  Use of Clomid in the past year or during the study

          -  Uncontrolled hypertension or diabetes mellitus based on the Investigator's assessment
             at baseline. Subjects treated for Type II diabetes but exhibiting glycemic control
             will be allowed into the study. Newly diagnosed diabetics need to be treated for at
             least 48 hours before being enrolled in the study.

          -  A hematocrit ≥51 % or a hemoglobin ≥17 g/dL

          -  Clinically significant abnormal findings on screening examination

          -  Use of an investigational drug or product, or participation in a drug or medical
             device research study within 30 days prior to receiving study medication

          -  Known hypersensitivity to Clomid

          -  Any condition which in the opinion of the investigator would interfere with the
             participant's ability to provide informed consent, comply with study instructions,
             possibly confound interpretation of study results, or endanger the participant if he
             took part in the study

          -  Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome,
             primary hypogonadism, vasectomy, or tumors of the pituitary)

          -  History of breast cancer

          -  History of prostate cancer or a suspicion of prostate disease unless ruled out by
             prostate biopsy, or a PSA &gt;3.6

          -  History of known hyperprolactinemia with or without a tumor

          -  Chronic use of medications use such as glucocorticoids

          -  Chronic use of narcotics

          -  Subjects known to be positive for HIV

          -  Subjects with end stage renal disease

          -  Subjects with cystic fibrosis (mutation of the CFTR gene)

          -  Subjects unable to provide a semen sample in the clinic

          -  Subject has a BMI &gt;42 kg/m2
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jolene Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centex Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.reprosrx.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <results_first_submitted>June 13, 2014</results_first_submitted>
  <results_first_submitted_qc>August 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2015</results_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Androxal 6.25 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="P2">
          <title>Androxal 12.5 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Androxal 25 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="P4">
          <title>AndroGel</title>
          <description>AndroGel 5G topical testosterone
Testosterone: topical gel
1X a day 6 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject incarcerated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to draw PK</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>T levels too high</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis consisted of all subjects enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Androxal 6.25 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>Androxal 12.5 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Androxal 25 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="B4">
          <title>AndroGel</title>
          <description>AndroGel 5G topical testosterone
Testosterone: topical gel
1X a day 6 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="8.8"/>
                    <measurement group_id="B2" value="51.7" spread="9.2"/>
                    <measurement group_id="B3" value="51.8" spread="13.0"/>
                    <measurement group_id="B4" value="53.5" spread="9.8"/>
                    <measurement group_id="B5" value="52.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="5.9"/>
                    <measurement group_id="B2" value="31.2" spread="6.6"/>
                    <measurement group_id="B3" value="31.6" spread="6.3"/>
                    <measurement group_id="B4" value="31.0" spread="6.1"/>
                    <measurement group_id="B5" value="31.8" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24 Hour Average and Maximum Testosterone Concentration</title>
        <description>The primary efficacy endpoint will be 24-hour average (TTavg) and maximum (TTmax) testosterone concentration compared to baseline after 6 weeks of treatment.
Time points (in hours after dosing) at which testosterone concentration was measured are: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24.</description>
        <time_frame>Baseline and Week 6</time_frame>
        <population>ITT, subjects who received at least one dose of study drug and had at least one post-dose efficacy measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Androxal 6.25 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Androxal 12.5 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Androxal 25 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>AndroGel</title>
            <description>AndroGel 5G topical testosterone
Testosterone: topical gel
1X a day 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Average and Maximum Testosterone Concentration</title>
          <description>The primary efficacy endpoint will be 24-hour average (TTavg) and maximum (TTmax) testosterone concentration compared to baseline after 6 weeks of treatment.
Time points (in hours after dosing) at which testosterone concentration was measured are: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24.</description>
          <population>ITT, subjects who received at least one dose of study drug and had at least one post-dose efficacy measure.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TTavg at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.3" spread="80.3"/>
                    <measurement group_id="O2" value="373.6" spread="172.1"/>
                    <measurement group_id="O3" value="298.3" spread="100.5"/>
                    <measurement group_id="O4" value="322.4" spread="102.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TTavg at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.4" spread="152.6"/>
                    <measurement group_id="O2" value="460.8" spread="129.1"/>
                    <measurement group_id="O3" value="586.7" spread="142.4"/>
                    <measurement group_id="O4" value="543.9" spread="229.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TTmax at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="358.5" spread="120.5"/>
                    <measurement group_id="O2" value="513.7" spread="222.2"/>
                    <measurement group_id="O3" value="425.9" spread="114.3"/>
                    <measurement group_id="O4" value="562.3" spread="488.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TTmax at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="524.5" spread="178.7"/>
                    <measurement group_id="O2" value="607.5" spread="167.7"/>
                    <measurement group_id="O3" value="764.3" spread="158.7"/>
                    <measurement group_id="O4" value="930.1" spread="550.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regression of 24 Hours Average Total Testosterone, Treatment Group and Morning Testosterone at Week 6.
Modeling 24 hour average total testosterone by morning testosterone and treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>P-value of treatment group.</p_value_desc>
            <method>Regression, Linear</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regression of 24 Hours Average Total Testosterone, Treatment Group and Morning Testosterone at Week 6.
Modeling 24 hour average total testosterone by morning testosterone and treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.436</p_value>
            <p_value_desc>P-value for Androxal 25 mg treatment group.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Regression Coefficient</param_type>
            <param_value>-45.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-143.5</ci_lower_limit>
            <ci_upper_limit>51.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regression of 24 Hours Average Total Testosterone, Treatment Group and Morning Testosterone at Week 6.
Modeling 24 hour average total testosterone by morning testosterone and treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>P-value for Androxal 12.5 mg group.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Regression Coefficient</param_type>
            <param_value>-110.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-210.6</ci_lower_limit>
            <ci_upper_limit>-11.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regression of 24 Hours Average Total Testosterone, Treatment Group and Morning Testosterone at Week 6.
Modeling 24 hour average total testosterone by morning testosterone and treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>P-value for Androxal 6.25 mg group.</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Regression Coefficient</param_type>
            <param_value>-148.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-242.9</ci_lower_limit>
            <ci_upper_limit>-54.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Regression of 24 Hours Average Total Testosterone, Treatment Group and Morning Testosterone at Week 6.
Modeling 24 hour average total testosterone by morning testosterone and treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for morning total testosterone (adjusted for treatment effect if treatment group is significant).</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Regression Coefficient</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leuteinizing Hormone (LH)</title>
        <description>Changes in morning LH after continuous dosing</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6</time_frame>
        <population>ITT, subjects who received at least one dose of study drug and had at least one post-dose efficacy measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Androxal 6.25 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Androxal 12.5 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Androxal 25 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>AndroGel</title>
            <description>AndroGel 5G topical testosterone
Testosterone: topical gel
1X a day 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leuteinizing Hormone (LH)</title>
          <description>Changes in morning LH after continuous dosing</description>
          <population>ITT, subjects who received at least one dose of study drug and had at least one post-dose efficacy measure.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning LH at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="1.55"/>
                    <measurement group_id="O2" value="4.82" spread="1.63"/>
                    <measurement group_id="O3" value="4.98" spread="3.45"/>
                    <measurement group_id="O4" value="3.57" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning LH at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" spread="2.69"/>
                    <measurement group_id="O2" value="8.60" spread="4.11"/>
                    <measurement group_id="O3" value="9.64" spread="5.04"/>
                    <measurement group_id="O4" value="2.00" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning LH Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="2.38"/>
                    <measurement group_id="O2" value="3.78" spread="3.29"/>
                    <measurement group_id="O3" value="4.66" spread="3.56"/>
                    <measurement group_id="O4" value="-1.57" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning LH at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="3.59"/>
                    <measurement group_id="O2" value="7.20" spread="2.97"/>
                    <measurement group_id="O3" value="11.78" spread="7.39"/>
                    <measurement group_id="O4" value="1.88" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning LH Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="3.20"/>
                    <measurement group_id="O2" value="2.38" spread="3.54"/>
                    <measurement group_id="O3" value="6.79" spread="5.54"/>
                    <measurement group_id="O4" value="-1.69" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning LH at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="3.3"/>
                    <measurement group_id="O2" value="8.2" spread="3.3"/>
                    <measurement group_id="O3" value="14.5" spread="10.5"/>
                    <measurement group_id="O4" value="2.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning LH Change from Baseline at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="3.32"/>
                    <measurement group_id="O2" value="3.39" spread="3.37"/>
                    <measurement group_id="O3" value="9.51" spread="8.15"/>
                    <measurement group_id="O4" value="-1.41" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA results - change from baseline in morning LH at Week 2. Modeling change from baseline by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for treatment group effect.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA results - change from baseline in morning LH at Week 4. Modeling change from baseline by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for treatment group effect.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA results - change from baseline in morning LH at Week 6. Modeling change from baseline by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for treatment group effect.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Morning Testosterone Correlated With Serial Testosterone.</title>
        <description>9 AM morning testosterone correlated with Week 6 serial testosterone Cavg, Cmin, and Cmax.
If a subject did not have a Week 6 serial testosterone Cavg, Cmin, or Cmax then they were not included for that particular correlation calculation.</description>
        <time_frame>Week 6</time_frame>
        <population>All Androxal subjects with Week 6 serial testosterone measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Androxal Pooled Dose Levels</title>
            <description>Androxal 6.25, 12.5, and 25 mg subjects combined into a single group.</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Testosterone Correlated With Serial Testosterone.</title>
          <description>9 AM morning testosterone correlated with Week 6 serial testosterone Cavg, Cmin, and Cmax.
If a subject did not have a Week 6 serial testosterone Cavg, Cmin, or Cmax then they were not included for that particular correlation calculation.</description>
          <population>All Androxal subjects with Week 6 serial testosterone measurements.</population>
          <units>Number of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pearson correlation between 9 am morning testosterone and serial testosterone Cavg at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Pearson Correlation</param_type>
            <param_value>0.90993</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pearson correlation between 9 am morning testosterone and serial testosterone Cmin at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Pearson Correlation</param_type>
            <param_value>0.86541</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Pearson correlation between 9 am morning testosterone and serial testosterone Cmax at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Pearson Correlation</param_type>
            <param_value>0.89643</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Enclomiphene Pharmacokinetic Parameters at Week 6 - Cmax.</title>
        <description>The Cmax for plasma concentration.</description>
        <time_frame>Week 6</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Androxal 6.25 mg</title>
            <description>Androxal 6.25 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Androxal 12.5 mg</title>
            <description>Androxal 12.5 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Androxal 25 mg</title>
            <description>Androxal 25 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Enclomiphene Pharmacokinetic Parameters at Week 6 - Cmax.</title>
          <description>The Cmax for plasma concentration.</description>
          <population>PK population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8154" spread="0.8358"/>
                    <measurement group_id="O2" value="3.3899" spread="2.0239"/>
                    <measurement group_id="O3" value="16.2993" spread="12.8952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Follicle Stimulating Hormone (FSH)</title>
        <description>Changes in morning FSH after continuous dosing</description>
        <time_frame>Baseline, Week 2, Week 4, Week 6</time_frame>
        <population>ITT, subjects who received at least one dose of study drug and had at least one post-dose efficacy measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Androxal 6.25 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Androxal 12.5 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Androxal 25 mg</title>
            <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O4">
            <title>AndroGel</title>
            <description>AndroGel 5G topical testosterone
Testosterone: topical gel
1X a day 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Follicle Stimulating Hormone (FSH)</title>
          <description>Changes in morning FSH after continuous dosing</description>
          <population>ITT, subjects who received at least one dose of study drug and had at least one post-dose efficacy measure.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning FSH at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" spread="1.97"/>
                    <measurement group_id="O2" value="5.63" spread="2.26"/>
                    <measurement group_id="O3" value="6.31" spread="4.28"/>
                    <measurement group_id="O4" value="6.38" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning FSH at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="2.56"/>
                    <measurement group_id="O2" value="7.77" spread="3.03"/>
                    <measurement group_id="O3" value="11.41" spread="8.19"/>
                    <measurement group_id="O4" value="3.80" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning FSH Change from Baseline at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.73"/>
                    <measurement group_id="O2" value="2.14" spread="2.15"/>
                    <measurement group_id="O3" value="5.09" spread="4.32"/>
                    <measurement group_id="O4" value="-2.58" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning FSH at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="2.70"/>
                    <measurement group_id="O2" value="7.12" spread="2.66"/>
                    <measurement group_id="O3" value="12.34" spread="9.59"/>
                    <measurement group_id="O4" value="3.72" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning FSH Change from Baseline at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="1.94"/>
                    <measurement group_id="O2" value="1.48" spread="2.58"/>
                    <measurement group_id="O3" value="6.03" spread="5.90"/>
                    <measurement group_id="O4" value="-2.66" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning FSH at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" spread="3.34"/>
                    <measurement group_id="O2" value="8.19" spread="3.25"/>
                    <measurement group_id="O3" value="13.45" spread="10.84"/>
                    <measurement group_id="O4" value="3.35" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morning FSH Change from Baseline at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="2.53"/>
                    <measurement group_id="O2" value="2.56" spread="2.53"/>
                    <measurement group_id="O3" value="7.14" spread="7.19"/>
                    <measurement group_id="O4" value="-3.03" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA results - change from baseline in morning FSH at Week 2. Modeling change from baseline by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for treatment group effect.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA results - change from baseline in morning FSH at Week 4. Modeling change from baseline by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for treatment group effect.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA results - change from baseline in morning FSH at Week 6. Modeling change from baseline by treatment group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for treatment group effect.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Enclomiphene Pharmacokinetic Parameters at Week 6 - Tmax.</title>
        <description>The Tmax for plasma concentration.</description>
        <time_frame>Week 6</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Androxal 6.25 mg</title>
            <description>Androxal 6.25 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Androxal 12.5 mg</title>
            <description>Androxal 12.5 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Androxal 25 mg</title>
            <description>Androxal 25 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Enclomiphene Pharmacokinetic Parameters at Week 6 - Tmax.</title>
          <description>The Tmax for plasma concentration.</description>
          <population>PK population</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.98"/>
                    <measurement group_id="O2" value="2.42" spread="1.21"/>
                    <measurement group_id="O3" value="2.41" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Enclomiphene Pharmacokinetic Parameters at Week 6 - AUC0-24.</title>
        <description>The area under the curve for plasma concentration over time from zero to 24 hours (AUC0-24).</description>
        <time_frame>Week 6</time_frame>
        <population>PK population</population>
        <group_list>
          <group group_id="O1">
            <title>Androxal 6.25 mg</title>
            <description>Androxal 6.25 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>Androxal 12.5 mg</title>
            <description>Androxal 12.5 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Androxal 25 mg</title>
            <description>Androxal 25 mg/day
Androxal (enclomiphene citrate): capsule oral
1X a day 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Enclomiphene Pharmacokinetic Parameters at Week 6 - AUC0-24.</title>
          <description>The area under the curve for plasma concentration over time from zero to 24 hours (AUC0-24).</description>
          <population>PK population</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.200" spread="14.399"/>
                    <measurement group_id="O2" value="34.012" spread="21.419"/>
                    <measurement group_id="O3" value="150.51" spread="132.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Androxal 6.25 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="E2">
          <title>Androxal 12.5 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="E3">
          <title>Androxal 25 mg</title>
          <description>enclomiphene citrate: capsule oral
1X a day 6 weeks</description>
        </group>
        <group group_id="E4">
          <title>AndroGel</title>
          <description>AndroGel 5G topical testosterone
Testosterone: topical gel
1X a day 6 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Allodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Libido increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary hesitancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer L. Wike</name_or_title>
      <organization>Repros Therapeutics Inc.</organization>
      <phone>281-719-3402</phone>
      <email>jwike@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

